DE60306202D1 - Oxazole als mglur1 verstärker - Google Patents

Oxazole als mglur1 verstärker

Info

Publication number
DE60306202D1
DE60306202D1 DE60306202T DE60306202T DE60306202D1 DE 60306202 D1 DE60306202 D1 DE 60306202D1 DE 60306202 T DE60306202 T DE 60306202T DE 60306202 T DE60306202 T DE 60306202T DE 60306202 D1 DE60306202 D1 DE 60306202D1
Authority
DE
Germany
Prior art keywords
mglur1
oxazole
amplifier
mglur1 amplifier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60306202T
Other languages
English (en)
Other versions
DE60306202T2 (de
Inventor
Joerg Huwyler
Frederic Knoflach
Eric Vieira
Juergen Wichmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60306202D1 publication Critical patent/DE60306202D1/de
Publication of DE60306202T2 publication Critical patent/DE60306202T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60306202T 2002-12-23 2003-12-17 Oxazole als mglur1 verstärker Expired - Lifetime DE60306202T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02028747 2002-12-23
EP02028747 2002-12-23
PCT/EP2003/014395 WO2004056814A1 (en) 2002-12-23 2003-12-17 Oxazoles as mglur1 enhancer

Publications (2)

Publication Number Publication Date
DE60306202D1 true DE60306202D1 (de) 2006-07-27
DE60306202T2 DE60306202T2 (de) 2007-06-06

Family

ID=32668736

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60306202T Expired - Lifetime DE60306202T2 (de) 2002-12-23 2003-12-17 Oxazole als mglur1 verstärker

Country Status (16)

Country Link
US (1) US7119113B2 (de)
EP (1) EP1578746B1 (de)
JP (1) JP4286788B2 (de)
KR (1) KR100713265B1 (de)
CN (1) CN100336813C (de)
AR (1) AR042643A1 (de)
AT (1) ATE329913T1 (de)
AU (1) AU2003298195B8 (de)
BR (1) BR0317714A (de)
CA (1) CA2511337C (de)
DE (1) DE60306202T2 (de)
ES (1) ES2265600T3 (de)
MX (1) MXPA05006657A (de)
PL (1) PL211061B1 (de)
RU (1) RU2345076C2 (de)
WO (1) WO2004056814A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016267A2 (en) * 2003-08-06 2005-02-24 Pfizer Products Inc. Oxazole compounds for the treatment of neurodegenerative disorders
AR057218A1 (es) 2005-12-15 2007-11-21 Astra Ab Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
WO2009098455A1 (en) * 2008-02-06 2009-08-13 Astrazeneca Ab 2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease
CN103319447B (zh) * 2013-06-18 2015-05-20 烟台万润精细化工股份有限公司 一种呫吨-9-羧酸的制备方法
US20210161910A1 (en) * 2019-12-02 2021-06-03 University Of Connecticut Combining BACE1 Inhibitors With mGluR Agonists For Alzheimer's Disease Therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803381B1 (en) * 1999-04-20 2004-10-12 Hoffmann-La Roche Inc. Carbamic acid derivatives
TW593241B (en) * 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives

Also Published As

Publication number Publication date
EP1578746B1 (de) 2006-06-14
AU2003298195A1 (en) 2004-07-14
RU2005123328A (ru) 2006-02-27
AR042643A1 (es) 2005-06-29
AU2003298195B8 (en) 2009-04-23
US7119113B2 (en) 2006-10-10
WO2004056814A1 (en) 2004-07-08
MXPA05006657A (es) 2005-08-16
RU2345076C2 (ru) 2009-01-27
BR0317714A (pt) 2005-11-22
EP1578746A1 (de) 2005-09-28
PL211061B1 (pl) 2012-04-30
CA2511337C (en) 2011-12-20
CA2511337A1 (en) 2004-07-08
ATE329913T1 (de) 2006-07-15
JP2006512343A (ja) 2006-04-13
AU2003298195B2 (en) 2009-04-02
CN1735610A (zh) 2006-02-15
PL377708A1 (pl) 2006-02-06
US20040132792A1 (en) 2004-07-08
KR100713265B1 (ko) 2007-05-04
CN100336813C (zh) 2007-09-12
ES2265600T3 (es) 2007-02-16
KR20050087848A (ko) 2005-08-31
JP4286788B2 (ja) 2009-07-01
DE60306202T2 (de) 2007-06-06

Similar Documents

Publication Publication Date Title
DE60301683D1 (de) Leseverstärker
CY2015036I2 (el) Νεα παραγωγα οξαζολιδινονης
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DK1654360T3 (da) Amplificering fremgangsmåde
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE60325032D1 (de) 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren
DE60315862D1 (de) Dihydropyridinonderivate als hne-inhibitoren
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
DK1531673T3 (da) Hidtil ukendt 2-pyridylethylbenzamidderivat
DE60313570D1 (de) Digitalverstärker
ATE478868T1 (de) Pyrrolodihydroisochinoline als pde10- inhibitoren
ATE411306T1 (de) Biarylsulfonamide als mmp-inhibitoren
DE602005006464D1 (de) Ramanverstärker
DE602004004230D1 (de) Klasse-D Verstärker
CR9144A (es) Formulaciones de benzoxazoles sustituidos
DE60328978D1 (de) Isochinolinderivate als mao-b inhibitoren
ATE538787T1 (de) Benzimidazol-derivative als raf-kinase-hemmer
ATE402700T1 (de) Glycinamid-derivate als raf-kinase-hemmer
DE602005001311D1 (de) Schaltverstärker
DE602004006997D1 (de) 4-(aminomethyl)-piperidinbenzamide als 5ht4 -antagonisten
DE60331026D1 (de) Ramanverstärker
SE0301107L (sv) Kraftförstärkare
DE602004004295D1 (de) 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition